Even though our data show that TNF-antagonist treatment can reduce BPH diagnosis, treatment with methotrexate, commonly prescribed as a non-specific anti-inflammatory agent in a number of AI diseases, actually increases BPH incidence in AI disease patients. The gene discussed is TNF; the disease is benign prostatic hyperplasia.